The file's text, extracted by GovTribe without its formatting.
FedBizOpps Presolicitation Notice
CLASSIFICATION CODE
SUBJECT
CONTRACTING OFFICE'S
ZIP-CODE
SOLICITATION NUMBER
RESPONSE DATE (MM-DD-YYYY)
ARCHIVE
DAYS AFTER THE RESPONSE DATE
RECOVERY ACT FUNDS
SET-ASIDE
NAICS CODE
CONTRACTING OFFICE
ADDRESS
POINT OF CONTACT
(POC Information Automatically Filled from User Profile Unless Entered)
DESCRIPTION
See Attachment
AGENCY'S URL
URL DESCRIPTION
AGENCY CONTACT'S EMAIL
ADDRESS
EMAIL DESCRIPTION
ADDRESS
POSTAL CODE
COUNTRY
ADDITIONAL INFORMATION
GENERAL INFORMATION
PLACE OF PERFORMANCE
* = Required Field FedBizOpps Presolicitation Notice Rev. March 2010
NUCLEAR MEDICINE RADIOPHARMACEUTICALS AND SEALED SOURCES
49037 36C25019Q0190 12-17-2018 N 325412 Department of Veteran Affairs Network Contracting Office 10 5500 Armstrong Rd.
Battle Creek MI 49037 Jeffrey P. Rozema Contract Specialist jeffrey.rozema@va.gov Department of Veterans Affairs Richard L. Roudebush VA Medical Center 1481 W. 10th Street Indianapolis, IN 46202 www.va.gov Agency Home Page jeffrey.rozema@va.gov Contract Specialist The Department of Veterans Affairs, Network Contracting Office 10, intends to solicit offers for radiopharmaceuticals and sealed sources for the Richard L. Roudebush VA Medical Center Nuclear Medicine Department. The radiopharmaceuticals and sealed sources will be delivered FOB Destination to the Nuclear Medicine Clinic, Room C-2187, 1481 W. 10th Street, Indianapolis, IN 46202 according to the terms and conditions stated in this solicitation. One Firm Fixed Price (FFP) Indefinite Delivery, Indefinite Quantity (IDIQ) contract for the period of 01/01/2019 – 09/30/2023 is anticipated. This is an unrestricted procurement for commercial items that will be conducted using FAR Part 13.5 procedures. NAICS code 325412 applies, and the small business size standard is 1,250 employees. The basis of award will be LPTA. The solicitation will be made available on or about 12/17/2018. The contract requirements are anticipated to be:
1.0 Summary:
Richard L. Roudebush VA Medical Center has a requirement for radiopharmaceuticals and radioactive sources for the nuclear medicine department. Due to the terms of USP<797>, the medical center can no longer compound radioisotopes in the facility’s existing hot lab. It is necessary to obtain these products and services that are both vital and critical to patient care from an outside nuclear pharmacy.
2.0 Requirements:
1. The contractor will meet all radiopharmaceutical requirements of RLR VA Medical Center in unit dose form. (See estimated quantities below)
2. The contractor will provide Non-Highly Enriched Uranium radiopharmaceuticals whenever possible in accordance with the VHA Memorandum dated 01-03-2014 from the VA Under Secretary for Health.
3. The contractor shall provide radioactive sealed sources necessary for patient care and quality control as outlined in the estimated quantities below.
4. The contractor shall provide Radiopharmaceuticals during standard hours of care Monday through Friday from 0700 (7:00 AM EST) until 1630 hours (4:30 PM EST), not including Federal holidays. After hours coverage will be available 24 hours Saturday and Sunday and Monday through Friday from 1630 (4:30 PM EST) until 0700 hours and including Federal holidays. Radioactive sealed sources will be delivered during normal business hours Monday through Friday from 0700-1630.
5. The contactor will be contacted by staff nuclear medicine technologists assigned to the nuclear medicine department at RLR VA Medical Center.
6. All routine orders for Radiopharmaceutical doses will be placed to the contractor one day before they are needed and prior to the clinic close of business via phone or internet. The order will include specified activities of doses and calibration times. The contractor will deliver the first run of ordered Radiopharmaceutical doses to the Nuclear Medicine Clinic, Room C-2187 before 0700 (EST) on the day specified to ensure proper inventory and receipt of the shipment is done by qualified personnel. A subsequent run of ordered radiopharmaceuticals will arrive by 1030 (EST) and if necessary a 3rd run will arrive for all add-on procedures ordered prior to the close of business. All emergency after hour orders of radiopharmaceutical doses will be placed by an on-call staff Nuclear Medicine Technologists on an emergency need basis. The contractor will deliver all after hour orders of Radiopharmaceuticals within two hours of the Radiopharmaceutical doses being ordered to the Nuclear Medicine Clinic, Room C-2187.
7. The contractor will calibrate all Radiopharmaceutical doses to ensure proper activity ranges of +/- 10 percent of the specified ordered dose based on specific requirements provided by Nuclear Medicine Clinic based on guidelines outlined in 10 CFR Part 35.
8. The contractor shall provide a daily packing slip accompanying all Radiopharmaceutical shipments to the Nuclear Medicine Clinic for all orders placed. The packing slip shall include a bar code that works with the Nuclear Medicine Information System (NMIS) for tracking purposes.
9. The contractor will ensure that all Radiopharmaceutical doses provided are compounded and calibrated by or under the supervision of a certified Nuclear Medicine Pharmacist.
10. The contractor shall provide courier service that is in accordance with Department of Transportation, Nuclear Regulatory Commission and other applicable regulating authorities enabling the delivery of all Radiopharmaceuticals. All couriers shall be licensed and shall submit all required paperwork to be granted access to RLR VA Medical Center, Indianapolis, Indiana. The contractor shall be responsible for the removal of all used and unused radiopharmaceutical doses from the clinic within 72 hours of delivery.
11. The contractor shall notify RLR VA Medical Center Nuclear Medicine Clinic immediately should the inability arise to provide Radiopharmaceutical doses.
12. The contractor shall provide any training or education required to meet commercial standards related to use of radiopharmaceuticals to all staff Nuclear Medicine Technologists stationed at RLR VA Medical Center.
3.0 The contractor shall be able to work within NMIS, the current Nuclear Medicine management program at RLR VA Medical Center. This shall allow for the receipt, inventory and proper documentation of Radiopharmaceutical doses dispensed.
Base Year (01/01/2019 – 09/30/2019)
Item Estimated Quantity Unit of Issue Unit Price Include Non-HEU and HEU
| 1 |
| GA-67 Citrate (per milicurie) |
| 5 |
| Dose |
| 2 |
| Tc-99m Sestamibi |
| 11 |
| Dose |
| Non-HEU/HEU |
| 3 |
| Tc-99m Mebrofenin |
| 60 |
| Dose |
| Non-HEU/HEU |
| 4 |
| Tc-99m MAA |
| 98 |
| Dose |
| Non-HEU/HEU |
| 5 |
| Tc-99m DTPA |
| 8 |
| Dose |
| Non-HEU/HEU |
| 6 |
| Tc-99m MAG3 |
| 53 |
| Dose |
| Non-HEU/HEU |
| 7 |
| Tc-99m MDP(Medronate) |
| 315 |
| Dose |
| Non-HEU/HEU |
| 8 |
| Tc-99 Ceretec |
| 4 |
| Dose |
| Non-HEU/HEU |
| 9 |
| Tc-99 Ceretec WBC |
| 15 |
| Dose |
| Non-HEU/HEU |
| 10 |
| Tc-99 Myoview(Tetrofosmin) |
| 2108 |
| Dose |
| Non-HEU/HEU |
| 11 |
| Tc99 Sulfur Colloid |
| 60 |
| Dose |
| Non-HEU/HEU |
| 12 |
| Tc99m Filtered Sulfur Colloid |
| 75 |
| Dose |
| Non-HEU/HEU |
| 13 |
| Tc99m NaTcO4 Calibration/Linearity Source |
| 8 |
| Dose |
| Non-HEU/HEU |
| 14 |
| Tl-201 Thallous Chloride(mCi) |
| 4 |
| Dose |
| 17 |
| In-111 Octreoscan |
| 8 |
| Dose |
| 18 |
| I-131 NAI Custom Therapy Capsules |
| 34 |
| Dose |
| 20 |
| I-123 200uCi Capsule |
| 3 |
| Dose |
| 21 |
| I-123 100uCi Capsule |
| 68 |
| Dose |
| 22 |
| I-123 Custom Capsule |
| 11 |
| Dose |
Year 2 (10/01/19 – 09/30/2020)
Estimated Quantity Unit of Issue Unit Price Include Non-HEU and HEU
| 1 |
| GA-67 Citrate (per milicurie) |
| 6 |
| Dose |
| 2 |
| Tc-99m Sestamibi |
| 15 |
| Dose |
| Non-HEU/HEU |
| 3 |
| Tc-99m Mebrofenin |
| 80 |
| Dose |
| Non-HEU/HEU |
| 4 |
| Tc-99m MAA |
| 130 |
| Dose |
| Non-HEU/HEU |
| 5 |
| Tc-99m DTPA |
| 10 |
| Dose |
| Non-HEU/HEU |
| 6 |
| Tc-99m MAG3 |
| 70 |
| Dose |
| Non-HEU/HEU |
| 7 |
| Tc-99m MDP(Medronate) |
| 420 |
| Dose |
| Non-HEU/HEU |
| 8 |
| Tc-99 Ceretec |
| 5 |
| Dose |
| Non-HEU/HEU |
| 9 |
| Tc-99 Ceretec WBC |
| 20 |
| Dose |
| Non-HEU/HEU |
| 10 |
| Tc-99 Myoview(Tetrofosmin) |
| 2810 |
| Dose |
| Non-HEU/HEU |
| 11 |
| Tc99 Sulfur Colloid |
| 80 |
| Dose |
| Non-HEU/HEU |
| 12 |
| Tc99m Filtered Sulfur Colloid |
| 100 |
| Dose |
| Non-HEU/HEU |
| 13 |
| Tc99m NaTcO4 Calibration/Linearity Source |
| 10 |
| Dose |
| Non-HEU/HEU |
| 14 |
| Tl-201 Thallous Chloride(mCi) |
| 5 |
| Dose |
| 17 |
| In-111 Octreoscan |
| 10 |
| Dose |
| 18 |
| I-131 NAI Custom Therapy Capsules |
| 45 |
| Dose |
| 20 |
| I-123 200uCi Capsule |
| 4 |
| Dose |
| 21 |
| I-123 100uCi Capsule |
| 90 |
| Dose |
| 22 |
| I-123 Custom Capsule |
| 15 |
| Dose |
Year 3 (10/01/2020 – 09/30/2021)
Estimated Quantity Unit of Issue Unit Price Include Non-HEU and HEU
| 1 |
| GA-67 Citrate (per milicurie) |
| 6 |
| Dose |
| 2 |
| Tc-99m Sestamibi |
| 15 |
| Dose |
| Non-HEU/HEU |
| 3 |
| Tc-99m Mebrofenin |
| 80 |
| Dose |
| Non-HEU/HEU |
| 4 |
| Tc-99m MAA |
| 130 |
| Dose |
| Non-HEU/HEU |
| 5 |
| Tc-99m DTPA |
| 10 |
| Dose |
| Non-HEU/HEU |
| 6 |
| Tc-99m MAG3 |
| 70 |
| Dose |
| Non-HEU/HEU |
| 7 |
| Tc-99m MDP(Medronate) |
| 420 |
| Dose |
| Non-HEU/HEU |
| 8 |
| Tc-99 Ceretec |
| 5 |
| Dose |
| Non-HEU/HEU |
| 9 |
| Tc-99 Ceretec WBC |
| 20 |
| Dose |
| Non-HEU/HEU |
| 10 |
| Tc-99 Myoview(Tetrofosmin) |
| 2810 |
| Dose |
| Non-HEU/HEU |
| 11 |
| Tc99 Sulfur Colloid |
| 80 |
| Dose |
| Non-HEU/HEU |
| 12 |
| Tc99m Filtered Sulfur Colloid |
| 100 |
| Dose |
| Non-HEU/HEU |
| 13 |
| Tc99m NaTcO4 Calibration/Linearity Source |
| 10 |
| Dose |
| Non-HEU/HEU |
| 14 |
| Tl-201 Thallous Chloride(mCi) |
| 5 |
| Dose |
| 17 |
| In-111 Octreoscan |
| 10 |
| Dose |
| 18 |
| I-131 NAI Custom Therapy Capsules |
| 45 |
| Dose |
| 20 |
| I-123 200uCi Capsule |
| 4 |
| Dose |
| 21 |
| I-123 100uCi Capsule |
| 90 |
| Dose |
| 22 |
| I-123 Custom Capsule |
| 15 |
| Dose |
Year 4 (10/01/2021 – 09/30/2022)
Estimated Quantity Unit of Issue Unit Price Include Non-HEU and HEU
| 1 |
| GA-67 Citrate (per milicurie) |
| 6 |
| Dose |
| 2 |
| Tc-99m Sestamibi |
| 15 |
| Dose |
| Non-HEU/HEU |
| 3 |
| Tc-99m Mebrofenin |
| 80 |
| Dose |
| Non-HEU/HEU |
| 4 |
| Tc-99m MAA |
| 130 |
| Dose |
| Non-HEU/HEU |
| 5 |
| Tc-99m DTPA |
| 10 |
| Dose |
| Non-HEU/HEU |
| 6 |
| Tc-99m MAG3 |
| 70 |
| Dose |
| Non-HEU/HEU |
| 7 |
| Tc-99m MDP(Medronate) |
| 420 |
| Dose |
| Non-HEU/HEU |
| 8 |
| Tc-99 Ceretec |
| 5 |
| Dose |
| Non-HEU/HEU |
| 9 |
| Tc-99 Ceretec WBC |
| 20 |
| Dose |
| Non-HEU/HEU |
| 10 |
| Tc-99 Myoview(Tetrofosmin) |
| 2810 |
| Dose |
| Non-HEU/HEU |
| 11 |
| Tc99 Sulfur Colloid |
| 80 |
| Dose |
| Non-HEU/HEU |
| 12 |
| Tc99m Filtered Sulfur Colloid |
| 100 |
| Dose |
| Non-HEU/HEU |
| 13 |
| Tc99m NaTcO4 Calibration/Linearity Source |
| 10 |
| Dose |
| Non-HEU/HEU |
| 14 |
| Tl-201 Thallous Chloride(mCi) |
| 5 |
| Dose |
| 17 |
| In-111 Octreoscan |
| 10 |
| Dose |
| 18 |
| I-131 NAI Custom Therapy Capsules |
| 45 |
| Dose |
| 20 |
| I-123 200uCi Capsule |
| 4 |
| Dose |
| 21 |
| I-123 100uCi Capsule |
| 90 |
| Dose |
| 22 |
| I-123 Custom Capsule |
| 15 |
| Dose |
Year 5 (10/01/2022 – 09/30/2023)
Estimated Quantity Unit of Issue Unit Price Include Non-HEU and HEU
| 1 |
| GA-67 Citrate (per milicurie) |
| 6 |
| Dose |
| 2 |
| Tc-99m Sestamibi |
| 15 |
| Dose |
| Non-HEU/HEU |
| 3 |
| Tc-99m Mebrofenin |
| 80 |
| Dose |
| Non-HEU/HEU |
| 4 |
| Tc-99m MAA |
| 130 |
| Dose |
| Non-HEU/HEU |
| 5 |
| Tc-99m DTPA |
| 10 |
| Dose |
| Non-HEU/HEU |
| 6 |
| Tc-99m MAG3 |
| 70 |
| Dose |
| Non-HEU/HEU |
| 7 |
| Tc-99m MDP(Medronate) |
| 420 |
| Dose |
| Non-HEU/HEU |
| 8 |
| Tc-99 Ceretec |
| 5 |
| Dose |
| Non-HEU/HEU |
| 9 |
| Tc-99 Ceretec WBC |
| 20 |
| Dose |
| Non-HEU/HEU |
| 10 |
| Tc-99 Myoview(Tetrofosmin) |
| 2810 |
| Dose |
| Non-HEU/HEU |
| 11 |
| Tc99 Sulfur Colloid |
| 80 |
| Dose |
| Non-HEU/HEU |
| 12 |
| Tc99m Filtered Sulfur Colloid |
| 100 |
| Dose |
| Non-HEU/HEU |
| 13 |
| Tc99m NaTcO4 Calibration/Linearity Source |
| 10 |
| Dose |
| Non-HEU/HEU |
| 14 |
| Tl-201 Thallous Chloride(mCi) |
| 5 |
| Dose |
| 17 |
| In-111 Octreoscan |
| 10 |
| Dose |
| 18 |
| I-131 NAI Custom Therapy Capsules |
| 45 |
| Dose |
| 20 |
| I-123 200uCi Capsule |
| 4 |
| Dose |
| 21 |
| I-123 100uCi Capsule |
| 90 |
| Dose |
| 22 |
| I-123 Custom Capsule |
| 15 |
| Dose |
No solicitation is available at this time. ***No response to this special notice is necessary*** For information about this solicitation, e-mail Jeffrey Rozema, Contract Specialist, at jeffrey.rozema@va.gov.